Amyotrophic Lateral Sclerosis Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed neurology journals, clinical publications, and authoritative rare disease organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), ALS Association (ALSA.org), Muscular Dystrophy Association (MDA), International Alliance of ALS Associations, National Institute of Neurological Disorders and Stroke (NINDS/NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) National ALS Registry, World Health Organization (WHO) Global Health Observatory, European ALS Registry (EURALS), Eurostat Health Database, National Health Service (NHS) England Rare Disease Registry, Japanese Ministry of Health Labour and Welfare (MHLW) pharmaceutical drugs database, and national health ministry reports from key markets. These sources were used to collect disease prevalence statistics, regulatory approval data for Riluzole and Edaravone, clinical safety and efficacy studies for gene therapies and antisense oligonucleotides, demographic trends in motor neuron disease, and competitive landscape analysis for pharmacotherapy, therapeutic devices, and emerging treatment modalities.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources comprised CEOs, VPs of Research & Development, chief medical officers, regulatory affairs heads, and commercial directors from pharmaceutical manufacturers (Biogen, Roche, Novartis, Sanofi, Amgen, Mitsubishi Tanabe Pharma), medical device manufacturers (ventilators, feeding tubes, communication aids), and emerging gene therapy developers. Demand-side sources included fellowship-trained neurologists who specialized in motor neuron diseases, ALS clinical care directors, multidisciplinary clinic coordinators, palliative care specialists, procurement leads from academic medical centers and tertiary care hospitals, and homecare service coordinators who managed ventilator and nutritional support. Market segmentation was validated across disease stages (early, middle, late), clinical pipeline timelines for investigational gene therapies were confirmed, and insights on treatment adoption patterns, reimbursement dynamics for orphan drugs, and patient transition flows between hospital and homecare settings were gathered, using primary research.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (40%), Director Level (30%), Others (30%)

• By Region: North America (40%), Europe (30%), Asia-Pacific (22%), Rest of World (8%)

Global market valuation was derived through revenue mapping and patient volume analysis. The methodology included:

• Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America spanning pharmacotherapy (small molecules, biologics, gene therapies), therapeutic devices (non-invasive ventilation, gastrostomy systems, augmentative communication devices), and palliative care services

• Product mapping across Riluzole formulations, Edaravone (oral and IV), Tofersen, emerging antisense therapies, and medical device categories specific to ALS management

• Analysis of reported and modeled annual revenues specific to ALS portfolios and patient management solutions

• Coverage of manufacturers representing 75-80% of global market share in 2024

• Extrapolation using bottom-up (prevalence patient volume × average treatment cost by country/region across oral, intravenous, and intrathecal administration routes) and top-down (manufacturer revenue validation and epidemiology-based modeling) approaches to derive segment-specific valuations for pharmacotherapy, therapeutic devices, and clinical trial participation markets